Persistent life-threatening hemorrhage after administration of idarucizumab

Am J Emerg Med. 2017 Jan;35(1):193.e3-193.e5. doi: 10.1016/j.ajem.2016.06.096. Epub 2016 Jun 30.

Authors

Hussain M Alhashem¹, Carmen Avendano¹, Bryan D Hayes², Michael E Winters³

Affiliations

¹ Emergency Medical Services, University of Maryland Medical Center, Baltimore, MD.
² Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD.
³ Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD. Electronic address: mwinters@em.umaryland.edu.

PMID: 27439386
DOI: 10.1016/j.ajem.2016.06.096

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Antidotes / therapeutic use*
Antithrombins / adverse effects*
Atrial Fibrillation / drug therapy
Dabigatran / adverse effects*
Duodenal Diseases / chemically induced*
Duodenal Diseases / therapy
Embolization, Therapeutic
Gastrointestinal Hemorrhage / chemically induced*
Gastrointestinal Hemorrhage / therapy
Humans
Male
Treatment Failure

Substances

Antibodies, Monoclonal, Humanized
Antidotes
Antithrombins
idarucizumab
Dabigatran